What happens to Medicaid spending when the first generic arrives

In 2015, state Medicaid programs paid for 478,774 prescriptions of the cholesterol drug rosuvastatin. Every one was filled with the brand-name product, and programs reimbursed pharmacies $110.0 million before rebates, or about $230 a prescription, according to federal State Drug Utilization Data⁸.

In 2024, Medicaid paid for 3.53 million rosuvastatin prescriptions, more than seven times as many. The 2024 data⁹ show $43.9 million in reimbursement, or $12.45 a prescription, almost all of it for generics.

That swing is what generic entry looks like from the payer's side, and Medicaid's records make it unusually visible because states report every drug code they pay for. Federal researchers have measured how far prices fall after a first generic arrives. GxRadar's NADAC files and Medicaid's own claims show how quickly the bill changes for four molecules, and what slows it down.

What federal research says about entry

The size of the price drop depends on how many makers enter. FDA economists looked at drugs whose first generics launched between 2015 and 2017 and published the results in a December 2019 report¹. Using average manufacturer prices reported to CMS, they found that with a single generic maker, the generic price was 39 percent below the brand price before competition. With two makers the gap was 54 percent, with four it was 79 percent, and with six or more it exceeded 95 percent. Invoice prices paid by pharmacies showed smaller but similar declines.

A January 2025 ASPE issue brief² using Medicare data from 2007 to 2022 reached the same shape by a different route. Prices fell by about 20 percent in markets with around three competitors and by 70 to 80 percent, relative to the pre-entry price, in markets with 10 or more competitors three years after first entry. ASPE also found the effect "stable over time" across entry cohorts.

Prices in the first months are the exception. A first filer that wins 180 days of exclusivity often shares the market only with the brand and, sometimes, an authorized generic. GxRadar explains the rules in 180-day exclusivity for first generic filers and the competitive pattern in why generic prices fall as competitors enter.

Four entries in the NADAC record

The National Average Drug Acquisition Cost survey records what retail pharmacies pay on invoice. GxRadar matched the first month a generic NADAC rate appeared for four drugs against the brand rate in the CMS files at the time (2013³, 2014⁴, 2016⁵ and 2018⁶), then tracked the generic rate a year later and in the October 2026 files⁷. First approval dates come from FDA's Drugs@FDA records via openFDA¹².

Generic NADAC figures are GxRadar's monthly medians of weekly rates for generic-classified products. Brand figures are the brand-classified rate for the same strength in the year's NADAC files.

In each case the first generic rate sat at 75 to 87 percent of the brand rate. FDA's invoice-based estimate for markets with one generic maker was 31 percent below brand, or 69 percent of it. Within a year it had fallen to between 2 and 12 percent of the brand. A month of 10 mg rosuvastatin at the 2016 brand rate cost a pharmacy $243.64 in ingredients; at the October 2026 generic rate it cost $1.07. The full histories are on each drug page and in how fast generic prices fell for rosuvastatin, duloxetine and tadalafil.

Rosuvastatin and duloxetine in Medicaid, year by year

Pharmacy invoice prices are one input. Medicaid's bill also depends on how fast prescriptions move to the generic and how many more people take the drug. GxRadar summed national rows of the State Drug Utilization Data (the same files behind its count of generic use in Medicaid) for each year and split them into brand and generic using CMS's drug category codes.

Two things stand out. Spending fell by more than half within two years of rosuvastatin's first generic, even though prescriptions rose. Later, volume outran the price decline. Prescriptions more than doubled between 2020 and 2024 while the cost per prescription fell 41 percent, so total spending rose from $32.1 million to $43.9 million. Duloxetine followed the same curve two years earlier. Medicaid's gross spending on it fell from $433.7 million in 2014 to $96.2 million in 2018 while prescriptions rose from 2.16 million to 3.94 million.

Valsartan shows the brand tail. In 2014, its first generic year, 71.9 percent of Medicaid prescriptions were still brand; by 2017 the share was 7.5 percent, and gross spending had fallen from $59.7 million to $27.2 million. Its NADAC then jumped in 2018, the year of the nitrosamine recalls covered in the valsartan recall and what it did to prices.

Why the Medicaid bill falls further, or less, than the price

Three program rules shape the result. States pay pharmacies an ingredient cost based on actual acquisition cost plus a dispensing fee, and many use NADAC as the yardstick, as GxRadar describes in how Medicaid pays for generic drugs. As invoice prices fall, the payment follows.

Federal upper limits add a ceiling once there is enough competition. Under 42 CFR 447.514¹⁰, CMS sets a limit for multiple-source drugs once FDA has rated at least three products as therapeutically equivalent. The limit equals 175 percent of the weighted average of the most recent monthly average manufacturer prices, unless that figure would fall below average retail acquisition cost.

Rebates pull the other way. Brand drugs carry a basic Medicaid rebate of at least 23.1 percent of average manufacturer price plus an inflation component, according to CMS's unit rebate amount rules¹¹, and generic drugs have a separate formula. Because the brand's rebate disappears as prescriptions move to generics, the net saving to Medicaid is smaller than the gross figures above suggest. The public files do not report rebates by drug, so GxRadar cannot measure the net change.

Across the whole market, the effect compounds. GxRadar's generic price index, built from NADAC rates for 43 common generics, stood at 47.4 in October 2026, against 100 in January 2014, a drop of about 53 percent. The full price series are on the prices page.

Prices after the fall

Entry is not the end of the story for every drug. Duloxetine's generic NADAC, after reaching a series low of 8.8 cents a capsule in December 2024, stood at 13.6 cents in October 2026, a rise of more than 50 percent in under two years. GxRadar tracks other cases in the generics that cost pharmacies more than they did in 2014.